HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Open in Screener

IMRX

Immuneering Corp

Last Close
Jul 14 • 04:00PM ET
4.17
Dollar change
-0.25
Percentage change
-5.66 		%
Healthcare • Biotechnology • USA • NASD
Peers: RCKT SRRK RNA SYRS STRO CUE MGTX CABA UBX ADAP
 | Held by: VTI VXF IWC AVSC CHNA
Index- P/E- EPS (ttm)-1.97 Insider Own28.28% Shs Outstand35.99M Perf Week2.96%
Market Cap150.06M Forward P/E- EPS next Y-1.58 Insider Trans1.27% Shs Float25.81M Perf Month96.70%
Enterprise Value118.27M PEG- EPS next Q-0.42 Inst Own12.50% Short Float6.68% Perf Quarter236.29%
Income-61.77M P/S- EPS this Y15.16% Inst Trans4.53% Short Ratio1.45 Perf Half Y108.50%
Sales0.00M P/B3.59 EPS next Y8.46% ROA-89.10% Short Interest1.72M Perf YTD89.55%
Book/sh1.16 P/C4.18 EPS next 5Y8.73% ROE-102.48% 52W High4.60 -9.35% Perf Year211.19%
Cash/sh1.00 P/FCF- EPS past 3/5Y-16.91% -46.45% ROIC-135.55% 52W Low1.00 317.00% Perf 3Y-26.19%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility12.20% 16.81% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-5.95% Oper. Margin- ATR (14)0.41 Perf 10Y-
Dividend Ex-Date- Quick Ratio7.48 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)68.17 Recom1.33
Dividend Gr. 3/5Y- - Current Ratio7.48 EPS Q/Q13.07% SMA2026.73% Beta0.37 Target Price11.42
Payout- Debt/Eq0.10 Sales Q/Q- SMA5083.77% Rel Volume0.88 Prev Close4.42
Employees66 LT Debt/Eq0.09 EarningsMay 05 AMC SMA200109.84% Avg Volume1.19M Price4.17
IPOJul 30, 2021 Option/ShortNo / Yes EPS/Sales Surpr.20.26% - Trades Volume1,049,690 Change-5.66%
Date Action Analyst Rating Change Price Target Change
Dec-13-24Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-15-24Reiterated Needham Buy $20 → $15
Mar-15-24Downgrade TD Cowen Outperform → Market Perform
Mar-15-24Downgrade Jefferies Buy → Hold $16 → $3
Dec-01-23Initiated Needham Buy $20
Jun-26-23Resumed Oppenheimer Outperform $25
Apr-19-23Upgrade Morgan Stanley Underweight → Equal-Weight $5 → $14
Apr-19-23Upgrade Mizuho Neutral → Buy $10 → $20
Mar-30-23Initiated Mizuho Neutral $10
Feb-03-23Downgrade Morgan Stanley Equal-Weight → Underweight $12 → $5
Show Previous Ratings
Jul-10-25 09:20AM
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
(PR Newswire)
Jul-09-25 08:00AM
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
(GlobeNewswire) +11.25%
Jul-08-25 04:00AM
The MEK effect on cancer a slow and steady approach to drug resistance
(Pharma Voice)
Jun-20-25 09:21AM
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
(PR Newswire) -7.58%
Jun-17-25 06:00AM
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
(GlobeNewswire) -23.21%
08:00AM Loading…
Jun-16-25 08:00AM
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
(GlobeNewswire) +24.74%
May-29-25 08:00AM
Immuneering to Present at the Jefferies Global Healthcare Conference
(GlobeNewswire) -5.83%
May-05-25 04:05PM
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
(GlobeNewswire)
Apr-02-25 08:00AM
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
(GlobeNewswire)
Mar-21-25 04:30PM
Immuneering Corporation Announces Grant of Inducement Award
(GlobeNewswire) +9.09%
Mar-20-25 04:05PM
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
(GlobeNewswire)
07:12AM
Immuneering names Igor Matushansky as chief medical officer
(SeekingAlpha)
07:00AM
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
(GlobeNewswire)
Feb-06-25 07:00AM
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo (cemiplimab)
(GlobeNewswire)
Feb-03-25 04:05PM
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
(GlobeNewswire)
08:00AM Loading…
Jan-13-25 08:00AM
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
(GlobeNewswire)
Jan-07-25 09:28AM
Why Is Immuneering Stock Trading Higher On Tuesday?
(Benzinga)
07:00AM
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
(GlobeNewswire)
Dec-23-24 10:49AM
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options
(PR Newswire) +10.00%
Dec-19-24 08:00AM
Immuneering Launches Pancreatic Cancer Advisory Board
(GlobeNewswire) +13.58%
Dec-17-24 08:00AM
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
(GlobeNewswire)
Dec-13-24 02:10PM
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
(Benzinga) -17.01%
Dec-12-24 08:00AM
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
(GlobeNewswire) -7.94%
Nov-27-24 08:00AM
Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference
(GlobeNewswire)
Nov-13-24 04:05PM
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire) -6.56% +13.45%
Oct-15-24 08:00AM
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
(GlobeNewswire) +15.50%
Sep-13-24 08:14AM
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
(Benzinga) +41.26%
Sep-12-24 04:05PM
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
(GlobeNewswire) +10.85%
Aug-29-24 08:00AM
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
(GlobeNewswire)
Aug-06-24 04:05PM
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire) -8.06%
04:05PM Loading…
Jul-31-24 04:05PM
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
(GlobeNewswire) +19.47%
May-29-24 04:05PM
Immuneering to Present at the Jefferies Global Healthcare Conference
(GlobeNewswire)
May-17-24 12:50PM
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment
(PR Newswire)
May-07-24 10:55PM
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
(InvestorPlace) -5.45%
04:05PM
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire)
May-06-24 04:30PM
Immuneering Recognizes Melanoma Awareness Month
(GlobeNewswire)
Apr-09-24 12:00PM
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
(GlobeNewswire)
Apr-03-24 04:05PM
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
(GlobeNewswire)
Mar-27-24 08:00AM
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
(GlobeNewswire)
Mar-18-24 11:02AM
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
(Zacks) +34.03%
Mar-14-24 07:00AM
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
(GlobeNewswire) -50.68%
Mar-12-24 08:00AM
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
(GlobeNewswire)
Mar-11-24 08:00AM
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
(GlobeNewswire) -9.53%
Mar-06-24 08:00AM
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
(Newsfile)
Mar-05-24 05:00PM
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
(GlobeNewswire)
Mar-04-24 08:00AM
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
(GlobeNewswire)
Mar-03-24 07:01PM
Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results
(GuruFocus.com)
Mar-01-24 08:00AM
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
(GlobeNewswire)
Feb-20-24 08:00AM
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
(GlobeNewswire)
Feb-14-24 03:45PM
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
(InvestorPlace) +8.00%
Feb-01-24 08:00AM
Immuneering Announces Participation in February Investor Conferences
(GlobeNewswire)
Dec-12-23 08:00AM
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
(GlobeNewswire) -7.11%
Nov-20-23 04:05PM
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
(GlobeNewswire) +25.45%
Nov-09-23 04:05PM
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
(GlobeNewswire) -11.86%
Oct-12-23 04:05PM
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
(GlobeNewswire) -6.65%
Oct-04-23 04:05PM
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Sep-06-23 08:00AM
Immuneering to Present at the Morgan Stanley Healthcare Conference
(GlobeNewswire)
Aug-03-23 04:05PM
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
(GlobeNewswire)
Aug-02-23 06:09AM
Immuneering Corporation (NASDAQ:IMRX) insiders have significant skin in the game with 28% ownership
(Simply Wall St.)
Jul-05-23 09:55AM
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet
(Zacks)
Jun-05-23 08:00AM
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
(GlobeNewswire)
May-30-23 08:00AM
Immuneering to Present at the Jefferies Healthcare Conference
(GlobeNewswire) +6.86%
May-04-23 07:25PM
Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates
(Zacks) -8.75%
04:05PM
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
(GlobeNewswire)
Apr-18-23 09:24AM
Immuneering Announces $30 Million Underwritten Offering
(GlobeNewswire) +9.60%
09:00AM
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
(GlobeNewswire)
04:20AM
Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?
(Zacks)
Apr-12-23 04:05PM
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
(GlobeNewswire)
Apr-11-23 03:56AM
Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?
(Zacks) +5.78%
Apr-05-23 08:00AM
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
(GlobeNewswire)
Mar-28-23 08:00AM
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
(GlobeNewswire) -7.40%
Mar-27-23 09:55AM
Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade
(Zacks)
Mar-24-23 01:25PM
Why Shares of Immuneering Jumped This Week
(Motley Fool)
Mar-23-23 06:18AM
Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?
(Zacks)
Mar-14-23 04:30PM
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
(GlobeNewswire) +5.62% -8.05%
Mar-09-23 09:55AM
Does Immuneering Corporation (IMRX) Have the Potential to Rally 210.19% as Wall Street Analysts Expect?
(Zacks) +5.47%
Mar-08-23 07:14AM
Immuneering Corporation (NASDAQ:IMRX) Q4 2022 Earnings Call Transcript
(Insider Monkey) +22.87%
Mar-06-23 05:45PM
Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates
(Zacks) +6.17%
04:05PM
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
(GlobeNewswire)
Mar-05-23 06:30PM
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
(GlobeNewswire)
Feb-28-23 08:00AM
Immuneering Announces Participation in March Investor Conferences
(GlobeNewswire)
Feb-27-23 08:00AM
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
(GlobeNewswire)
Feb-05-23 07:18AM
Immuneering Corporation (NASDAQ:IMRX) insiders, who hold 31% of the firm would be disappointed by the recent pullback
(Simply Wall St.)
Jan-31-23 06:50AM
Immuneering To Present at Guggenheim 2023 Oncology Conference
(GlobeNewswire)
Nov-28-22 06:50AM
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
(GlobeNewswire)
Nov-16-22 06:35AM
Immuneering Third Quarter 2022 Earnings: Revenues Disappoint
(Simply Wall St.)
Nov-10-22 10:15AM
Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
09:00AM
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
(GlobeNewswire)
09:00AM
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC
(GlobeNewswire)
Nov-03-22 06:50AM
Immuneering Announces Participation in November Investor Conferences
(GlobeNewswire) -12.80%
Oct-20-22 06:50AM
Immuneering Appoints Leah R. Neufeld as Chief People Officer
(GlobeNewswire)
Oct-05-22 08:05AM
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
(GlobeNewswire) -5.80%
Sep-30-22 12:00PM
What Makes Immuneering Corporation (IMRX) a New Buy Stock
(Zacks) +9.15%
06:50AM
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
(GlobeNewswire)
Sep-12-22 09:55AM
Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High?
(Zacks) +10.82%
Sep-05-22 10:21AM
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104
(Zacks)
Sep-02-22 08:09AM
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
(GlobeNewswire) +7.05%
Aug-25-22 09:55AM
Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to Trade
(Zacks) -7.35%
06:50AM
Immuneering Announces Participation in September Investor Conferences
(GlobeNewswire)
Aug-10-22 05:55PM
Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HAUSMAN DIANADirectorJul 02 '25Buy3.623,00010,8743,000Jul 07 08:59 AM
HAUSMAN DIANADirectorJul 02 '25Buy3.602,5008,9892,500Jul 07 08:59 AM
Neufeld Leah RCHIEF PEOPLE OFFICERJul 02 '25Buy3.577002,49910,729Jul 07 08:52 AM
Zeskind Benjamin J.PRESIDENT AND CEOJul 02 '25Buy3.537,01524,7922,312,852Jul 03 09:12 AM
Zeskind Benjamin J.PRESIDENT AND CEOJul 01 '25Buy3.382,98510,0872,305,837Jul 03 09:12 AM
Schall Thomas J.DirectorJun 27 '25Buy3.669,50034,78852,885Jun 30 09:09 AM
Hall Brett MatthewCHIEF SCIENTIFIC OFFICERJun 20 '25Buy2.707,41520,020353,311Jun 24 09:01 AM
Hall Brett MatthewCHIEF SCIENTIFIC OFFICERJun 23 '25Buy2.436,00714,596359,318Jun 24 09:01 AM
Brakewood Harold EugeneChief Business OfficerJun 20 '25Buy2.531,9004,8045,800Jun 24 08:52 AM
Feinberg PeterDirectorJun 18 '25Buy2.5325,00063,188136,766Jun 23 09:09 AM
Zeskind Benjamin J.PRESIDENT AND CEOJun 18 '25Buy2.3921,00050,1442,302,852Jun 20 09:09 AM
Schall Thomas J.DirectorJun 17 '25Buy2.2140,48589,27843,385Jun 18 09:11 AM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

ZNTL

Zentalis Pharmaceuticals Inc

Last Close
Jul 14 • 04:00PM ET
1.36
Dollar change
+0.03
Percentage change
2.26 		%
Healthcare • Biotechnology • USA • NASD
ZNTL Zentalis Pharmaceuticals Inc daily Stock Chart
Peers: BMY LLY PFE JNJ MRK AMGN GILD BIIB VRTX REGN
 | Held by: VTI VXF VTWO SCHA PRFZ FESM IWC VHT DFAS VTWV
Index- P/E- EPS (ttm)-3.15 Insider Own22.85% Shs Outstand71.95M Perf Week14.29%
Market Cap97.86M Forward P/E- EPS next Y-2.06 Insider Trans0.70% Shs Float55.51M Perf Month-8.11%
Enterprise Value-195.94M PEG- EPS next Q-0.55 Inst Own76.26% Short Float9.14% Perf Quarter20.35%
Income-224.19M P/S3.64 EPS this Y1.13% Inst Trans-11.56% Short Ratio5.05 Perf Half Y-51.08%
Sales26.86M P/B0.33 EPS next Y10.36% ROA-47.62% Short Interest5.07M Perf YTD-55.12%
Book/sh4.11 P/C0.29 EPS next 5Y5.90% ROE-59.45% 52W High5.44 -75.00% Perf Year-65.48%
Cash/sh4.62 P/FCF- EPS past 3/5Y14.39% -12.89% ROIC-67.11% 52W Low1.01 34.65% Perf 3Y-95.58%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin95.43% Volatility8.07% 8.68% Perf 5Y-96.81%
Dividend TTM- EV/Sales-7.29 EPS Y/Y TTM6.23% Oper. Margin-742.11% ATR (14)0.11 Perf 10Y-
Dividend Ex-Date- Quick Ratio6.94 Sales Y/Y TTM-33.76% Profit Margin-834.49% RSI (14)53.18 Recom2.00
Dividend Gr. 3/5Y- - Current Ratio6.94 EPS Q/Q-576.38% SMA204.17% Beta1.70 Target Price6.86
Payout- Debt/Eq0.13 Sales Q/Q-100.00% SMA503.30% Rel Volume0.75 Prev Close1.33
Employees166 LT Debt/Eq0.13 EarningsMay 14 AMC SMA200-39.73% Avg Volume1.00M Price1.36
IPOApr 03, 2020 Option/ShortYes / Yes EPS/Sales Surpr.-5.08% - Trades Volume748,902 Change2.26%
Date Action Analyst Rating Change Price Target Change
Aug-12-24Upgrade Wedbush Underperform → Neutral $4
Jun-20-24Downgrade UBS Buy → Neutral $28 → $5
Jun-18-24Downgrade Wells Fargo Overweight → Equal Weight
Jun-18-24Downgrade Wedbush Neutral → Underperform $15 → $4
Jun-18-24Downgrade Morgan Stanley Overweight → Equal-Weight $38 → $8
Jun-18-24Downgrade Jefferies Buy → Hold $42 → $6
Nov-08-23Downgrade Wedbush Outperform → Neutral $38 → $12
Nov-07-23Downgrade Leerink Partners Outperform → Market Perform $15
Jul-12-22Initiated Cowen Outperform
Apr-06-22Initiated Wells Fargo Overweight $67
Show Previous Ratings
Jul-01-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-02-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +5.79% +6.25%
May-14-25 04:05PM
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
(GlobeNewswire) +5.88%
May-01-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-28-25 08:00AM
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
(GlobeNewswire)
04:05PM Loading…
Apr-23-25 04:05PM
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
(GlobeNewswire)
Apr-01-25 05:30PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -12.58%
Mar-26-25 04:05PM
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
(GlobeNewswire) -5.88%
Mar-25-25 04:40PM
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
(GlobeNewswire) -5.56%
Mar-15-25 11:25AM
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
(GlobeNewswire)
Mar-03-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -7.25%
08:00AM
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
(GlobeNewswire)
Feb-24-25 04:05PM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Feb-21-25 12:21AM
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently
(Insider Monkey) -6.07%
Feb-03-25 05:42PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
09:35AM Loading…
09:35AM
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Jan-30-25 10:20AM
Zentalis price target lowered to $10 from $20 at Oppenheimer
(TipRanks) -12.17%
Jan-29-25 07:00AM
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
(GlobeNewswire) -21.25%
Jan-28-25 04:05PM
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
(GlobeNewswire)
Jan-09-25 12:00PM
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
(Zacks)
07:00AM
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies
(GlobeNewswire)
Jan-02-25 04:53PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +8.00%
Dec-12-24 07:00AM
Zentalis Pharmaceuticals Announces Key Management Appointments
(GlobeNewswire) -10.57%
Dec-02-24 04:35PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -8.20%
Nov-13-24 08:00AM
Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
(GlobeNewswire) +5.66%
Nov-01-24 07:04PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +21.61% +12.35%
Oct-18-24 03:05PM
State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings
(GuruFocus.com)
Oct-07-24 03:03PM
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
(GuruFocus.com) -7.72%
Sep-17-24 12:15PM
FDA lifts partial clinical hold on Zentalis Pharmas cancer WEE1 inhibitor
(Pharmaceutical Technology) +11.41%
Sep-16-24 09:00AM
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
(Benzinga) +13.58%
07:00AM Loading…
07:00AM
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
(GlobeNewswire)
Sep-09-24 07:00AM
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
(GlobeNewswire)
Sep-03-24 04:40PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -6.92%
Aug-26-24 11:58AM
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
(Zacks)
Aug-09-24 02:53PM
ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024
(InvestorPlace) -9.37%
07:00AM
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
(GlobeNewswire)
Aug-01-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -5.00%
Jul-01-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -14.80%
Jun-19-24 10:23AM
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
(Zacks)
04:52AM
FDA places partial clinical hold on Zentalis trials of azenosertib for cancer
(Clinical Trials Arena)
Jun-18-24 07:00AM
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
(GlobeNewswire) -50.66%
Jun-03-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-01-24 02:43AM
Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ...
(GuruFocus.com)
May-30-24 07:00AM
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
(GlobeNewswire)
May-29-24 07:00AM
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
(GlobeNewswire)
May-23-24 05:01PM
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
(GlobeNewswire) -5.84%
May-14-24 07:00AM
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
(GlobeNewswire)
May-08-24 10:27AM
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating
(MT Newswires)
May-07-24 09:04PM
Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ...
(GuruFocus.com) +5.03%
01:54PM
ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024
(InvestorPlace)
07:00AM
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
(GlobeNewswire)
May-01-24 05:30PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-02-24 04:05PM
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
(GlobeNewswire) -10.54% +8.25%
Apr-01-24 05:30PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Mar-01-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Feb-28-24 09:55AM
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
(Zacks) +5.30%
07:00AM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Feb-27-24 07:01PM
Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ...
(GuruFocus.com)
07:00AM
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
(GlobeNewswire)
Feb-14-24 09:35AM
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
(Zacks) +10.34%
Feb-13-24 07:00AM
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
(GlobeNewswire) -5.83%
Feb-08-24 12:00PM
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
(Zacks)
Feb-05-24 11:26PM
Insider Sell: President Cam Gallagher Sells 11,552 Shares of Zentalis Pharmaceuticals Inc (ZNTL)
(GuruFocus.com)
Feb-01-24 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jan-25-24 07:00AM
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
(GlobeNewswire)
Jan-08-24 07:00AM
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
(Business Wire) +7.15%
Jan-02-24 04:49PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +5.54%
Dec-01-23 05:39PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Nov-13-23 09:03PM
Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares
(GuruFocus.com) +14.42%
Nov-09-23 07:00AM
Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen
(GlobeNewswire)
Nov-06-23 07:13PM
Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates
(GuruFocus.com) -30.20% -18.27%
07:18AM
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
(GlobeNewswire)
Nov-01-23 04:52PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Oct-07-23 05:00AM
Insider Sell: Chief Medical Officer Carrie Brownstein Sells 10,628 Shares of Zentalis ...
(GuruFocus.com)
Oct-02-23 04:27PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Sep-14-23 01:02AM
Director Jan Skvarka Sells 5,000 Shares of Zentalis Pharmaceuticals Inc (ZNTL)
(GuruFocus.com)
Sep-06-23 07:00AM
Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
(GlobeNewswire)
Sep-01-23 04:37PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -6.34%
Aug-09-23 07:00AM
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
(GlobeNewswire)
Aug-01-23 04:28PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
07:00AM
Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer
(GlobeNewswire)
Jun-15-23 06:01AM
Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock
(GlobeNewswire) +12.67%
Jun-06-23 06:00AM
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
(GlobeNewswire)
Jun-02-23 02:34PM
Why Shares of Zentalis Pharmaceuticals Dropped This Week
(Motley Fool)
May-26-23 12:33PM
Wells Fargo Predicts up to 70% Rally for These 2 Stocks Heres Why They Have Solid Upside
(TipRanks) +10.64%
10:53AM
Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes
(Benzinga)
May-25-23 05:38PM
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
(GlobeNewswire)
May-23-23 07:00AM
Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations
(GlobeNewswire)
May-12-23 09:55AM
Wall Street Analysts Believe Zentalis Pharmaceuticals, Inc. (ZNTL) Could Rally 95.67%: Here's is How to Trade
(Zacks)
May-10-23 07:00AM
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
(GlobeNewswire) +6.93%
Apr-26-23 10:00AM
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting
(GlobeNewswire)
Apr-17-23 09:00AM
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
(GlobeNewswire) +7.51%
Mar-01-23 07:00AM
Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates
(GlobeNewswire)
Feb-13-23 07:00AM
Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer
(GlobeNewswire)
Feb-01-23 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
07:01AM
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
Jan-17-23 09:18AM
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
(Simply Wall St.)
Jan-03-23 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Dec-08-22 09:55AM
Can Zentalis Pharmaceuticals, Inc. (ZNTL) Climb 170% to Reach the Level Wall Street Analysts Expect?
(Zacks)
Dec-01-22 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myers Scott DunsethDirectorApr 30 '25Buy1.4021,00029,373281,192Apr 30 05:07 PM
Bruns IngmarChief Medical OfficerFeb 06 '25Buy2.2820,00045,65636,629Feb 12 05:00 PM
Cam GallagherFormer DirectorFeb 11 '25Proposed Sale2.006871,374Feb 11 08:06 PM
Vultaggio VincentPAO and Interim PFOFeb 03 '25Sale1.712,6154,476189,826Feb 05 06:33 PM
Lackner MarkChief Scientific OfficerFeb 03 '25Sale1.7114,36824,591512,856Feb 05 06:32 PM
Paul AndreaChief Legal OfficerFeb 03 '25Sale1.7113,23022,6431,070,784Feb 05 06:31 PM
Skvarka JanDirectorJan 31 '25Buy1.7260,000103,446149,551Feb 04 04:45 PM
Walker Luke NathanielDirectorJan 31 '25Buy1.7614,20024,96686,681Feb 04 04:43 PM
EASTLAND JULIA MARIECEO & PresidentJan 31 '25Buy1.7328,50049,34528,500Feb 04 04:37 PM
Mark LacknerChief Scientific OfficerFeb 03 '25Proposed Sale1.7114,36824,591Feb 03 07:14 PM
Andrea PaulChief Legal Officer & CorporatFeb 03 '25Proposed Sale1.7113,23022,643Feb 03 07:13 PM
Cam GallagherFormer DirectorFeb 03 '25Proposed Sale1.7128,55848,877Feb 03 07:12 PM
Lackner MarkChief Scientific OfficerJan 02 '25Sale3.124,41113,762191,317Jan 03 05:17 PM
Diana HausmanFormer Chief Medical OfficerOct 31 '24Proposed Sale2.869,88828,294Oct 31 08:59 PM
Vultaggio VincentPrincipal Accounting OfficerOct 04 '24Sale3.181,6035,09833,855Oct 04 06:01 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.